深圳爱科思达科技有限公司

广州法莱模具设计有限公司

广州法莱模具设计有限公司
招聘简章

一．企业介绍
广州法莱模具设计有限公司致力于为全球挤压模具制造企业提供专业的模具设计及相关领域的专业技术方案。广州法莱是欧洲领先铝型材挤压模具制造商PHOENIX NEDERLAND B.V.在中国设立的分支机构，集团总部位于意大利。PHOENIX集团是欧洲铝型材行业的领军企业，在欧洲大陆、荷兰、西班牙、德国、迪拜、美国等地设有分支机构和工厂。其主营业务包括：
1. 运输业：高速列车车厢的主体形状零件、结构性零件等模具。
2. 建筑业：用于住宅和商用建筑物内部的型材模具，例如摩天大楼的外墙。
3. 汽车业：汽车保险杠、减震器、防侵入杆、发动机支架等铝型材模具。
4. 航空业：飞机机翼内部的主体形状零件、结构性零件等的韧性合金模具。

广州法莱模具设计有限公司获得政府授予的“技术先进型服务企业”、“广州市科技创新小巨人企业”等荣誉，并于2017年获得国家颁发的“高新技术企业证书”。目前处于快速发展阶段，为满足业务需求，现诚聘模具设计技术人员。一经录用，公司将提供系统的培训及良好的职业发展机会。

二、公司薪酬福利
1. 薪酬：月薪3000-6000元+绩效奖金。
2. 工作时间：每周40小时，超时加班按国家规定支付1.5-3倍加班费。
3. 保险：为员工缴纳五险一金（养老保险、失业保险、工伤保险、医疗保险、生育保险和住房公积金），并对表现优秀的员工额外提供商业保险，涵盖门诊和住院费用。
4. 节假日：员工享有带薪年假、婚假、产假、丧假等。
5. 各项活动：节日福利、年度旅游、年度健康体检等。
6. 公司提供完善的培训机制，培训周期从3个月到6个月不等。优秀员工有机会前往意大利总部进行深入培训。公司为每位员工提供良好的培训和发展空间，实现企业和员工的双赢。

三、应聘方式
请将简历发送至E-mail: HRrecruitment.FARA@phoenix-spa.com，并在邮件主题中注明姓名、应聘职位及联系方式。

广州润生细胞医药科技有限责任公司

Guangzhou Runsheng Cytomed Technology Co., Ltd. is a Sino-foreign joint venture biotechnology enterprise dedicated to cell medicine R&D and clinical translational research. The founder and academic leader of the company, Professor Ruan Runsheng, holds a postdoctoral degree from the University of Zurich in Switzerland, is a senior researcher at the National University of Singapore's Department of Medicine, a chief researcher at the Institute of Bioengineering and Nanotechnology of the Singapore Science and Technology Agency, and a member of the European Society of Medical Oncology (ESMO). He has also been included in the US New Century 500 Scientists and the Marquis' Who's Who Yearbook of the United States. Professor Ruan Runsheng has long been committed to the research and development of cellular immunology, with his latest achievement being the Tvac？ tumor personalized precision combined immunotherapy technology.

Founded on September 24, 2019, in Nansha, Guangzhou, the company focuses on exploring and developing the clinical applications of Tvac？ tumor personalized precision combined immunotherapy technology. This technology uses genomics, proteomics, and other omics technologies along with tumor immunology to achieve individualized precision treatment, marking an important direction for future cancer treatments.

Currently, the company has established four platforms: bioinformatics, proteomics, peptide synthesis, and cellular immunity. These platforms are equipped with high-speed local servers and cloud platforms, ultra-high-throughput 106-channel peptide synthesizers, liquid mass spectrometers, PCR instruments, Elispot, flow cytometers, RTCA, and cell culture rooms. These advanced facilities ensure robust support for the screening of new antigens and the development of peptide drugs. The company has built a highly specialized technical R&D team leveraging its platform advantages. Core team members come from prestigious institutions such as the Hong Kong University of Science and Technology, Technical University of Denmark, Stanford University School of Medicine, Harvard Medical School, and Macquarie University in Australia, all holding master's or doctoral degrees. Their expertise spans molecular biology, biochemistry, tumor immunology, clinical medicine, and industrialization.

The company has established strategic partnerships with institutions such as the National University Hospital of Singapore, Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center, the First Affiliated Hospital of Sun Yat-sen University, the Second Affiliated Hospital of Guangzhou Medical College, Guangdong Provincial People's Hospital, and Guangzhou First People's Hospital. Tvac？ technology is undergoing steady clinical trials, with smooth progress. Plans are underway to submit an NDA for Tvac？ within the next three years, aiming for formal clinical application in tumor treatment. Simultaneously, the company is advancing other tumor cell therapy R&D and clinical translation projects.

In 2021, the company partnered with the Guangdong-Hong Kong-Macao Greater Bay Area Postdoctoral Science and Technology Innovation Public Research Center to establish a postdoctoral research station, continuously attracting and nurturing high-end biomedical talent. It aims to provide a platform for international researchers pursuing the dream of medical practice.

The company is currently staffed primarily by R&D personnel, with two foreign experts, and maintains a flexible organizational structure and fresh corporate culture. It is a dynamic and energetic cell medicine R&D team with international vision and top-tier standards. Moving forward, the company will closely align with market demands, applying professional technology to medical institutions and patients, and creating an innovative technology platform that integrates scientific development, talent cultivation, and shared benefits.

北京世通仁和数码科技有限公司

北京世通仁和数码科技有限公司，规模为50-150人，类型为民营公司，行业为餐饮业。

金蝶软件杭州

金蝶国际软件集团始创于1993年，是香港联交所主板上市公司（股票代码：0268）。金蝶是中国企业管理软件及云服务市场的领跑者，20多年来，金蝶已帮助超过500万家企业实现管理进步，金蝶系的互联网服务用户超过2亿人。IDC权威数据显示：金蝶连续11年稳居中国中小企业ERP市场占有率第一名。

金蝶（中国）有限公司杭州分公司成立于1996年，历经20年发展，拥有百名员工和50家合作伙伴，为2万余家客户提供企业信息化服务，是浙江省十佳软件服务企业，浙江省管理软件首选品牌。